<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268498</url>
  </required_header>
  <id_info>
    <org_study_id>19-339</org_study_id>
    <nct_id>NCT04268498</nct_id>
  </id_info>
  <brief_title>A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Standard of Care to Determine MRD Negativity in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone
      (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling
      multiple myeloma than the stand or care treatment, which is lenalidomide, bortexomib, and
      dexamethasone (VRD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in measurable residual disease/MRD negativity for participants who received VRD/Arm A to participants who receive KRD/Arm B and participants who receive KRD + DARA/Arm C</measure>
    <time_frame>32 weeks from baseline</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A (VRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed patients with histologically confirmed multiple myeloma (MM).
bortezomib, lenalidomide, dexamethasone (VRD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (KRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed patients with histologically confirmed multiple myeloma (MM).
carfilzomib, lenalidomide, and dexamethasone (KRD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed patients with histologically confirmed multiple myeloma
daratumumab, carfilzomib, lenalidomide, and dexamethasone (KRD+DARA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Arm A: Cycles 1-8: Bortezomib 1.3 mg/m2 SC or IV days 1, 4, 8, 11 of 21 day treatment cycles</description>
    <arm_group_label>Arm A (VRD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Arm A:
Dexamethasone 20 mg/dose PO or IV on days of Bortezomib infusion;
Arm B:
Cycle 1 - Dexamethasone, 40mg/dose days 1, 8 and 15 IV or PO Cycle 2 - Dexamethasone 40 mg/dose, days 1, 8, and 15 IV or PO Cycle 3-4 - Dexamethasone 40mg/dose, Days 1, 8, 15 IV or PO Cycle 5-8 - Dexamethasone 20mg/dose, Days 1, 8, 15
Arm C:
Cycle 1 - Dexamethasone 20 mg/dose, days 1,2, and 22, 40mg/dose days 8 and 15 Cycle 2 - Dexamethasone 40 mg/dose, days 1, 8, and 15 IV or PO ; 20mg/dose day 22 Cycles 3-4 - Dexamethasone 40mg/dose, Days 1, 8, 15 IV or PO Cycles 5-8 - Dexamethasone 20mg/dose, Days 1, 8, 15</description>
    <arm_group_label>Arm A (VRD)</arm_group_label>
    <arm_group_label>Arm B (KRD)</arm_group_label>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Arm A:
Cycles 1-8 - Lenalidomide 25 mg/day, days 1-14 of 21 day treatment cycles
Arm B:
Cycle 1 - Lenalidomide 25 mg/day, days 2-21 every 28 days Cycles 2-8 - Lenalidomide 25 mg/day, days 1-21 every 28 days
Arm C:
Cycle 1 - Lenalidomide 25 mg/day, days 2-21 every 28 days Cycle 2-8 - Lenalidomide 25 mg/day, days 1-21 every 28 days</description>
    <arm_group_label>Arm A (VRD)</arm_group_label>
    <arm_group_label>Arm B (KRD)</arm_group_label>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Arm C:
Cycle 1 - days 2-21 every 28 days; Acetaminophen 650 mg Cycle 2-8 - Acetaminophen 650 mg</description>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Arm C:
Cycle 1-8 - intravenous Diphenhydramine 25 mg</description>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Arm C:
Montelukast 10 mg will be administered prior to the first 4 doses of Daratumumuab</description>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Arm B:
Cycle 1 - Carfilzomib 20 mg/m^2 per dose, day 1; Carfilzomib 56 mg/m2 per dose, days 8 and 15 Cycle 2-8 - Carfilzomib 56 mg/m2 per dose, days 1, 8, and 15
Arm C:
Cycle 1 - Carfilzomib 20 mg/m2 per dose, day 2; Carfilzomib 56 mg/m2 per dose, days 8 and 15 Cycles 2-8: Carfilzomib 56 mg/m2 per dose, days 1, 8, and 15</description>
    <arm_group_label>Arm B (KRD)</arm_group_label>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Arm C:
Cycle 1-2 - Daratumumab 16 mg/kg days 1, 8, 15, and 22 Cycle 3-6- Daratumumab 16 mg/kg days 1 and 15 Cycle 7-8 - Daratumumab 16 mg/kg day 1</description>
    <arm_group_label>Arm C (KRD + DARA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients with histologically confirmed MM based on the following
             criteria:

               -  Clonal plasma cells in the bone marrow

               -  Measurable disease within the past 4 weeks defined by any one of the following:

               -  Serum monoclonal protein &gt;/= 1.0 g/dL

               -  Urine monoclonal protein &gt;/= 200 mg/24 hour

               -  Involved serum immunoglobulin free light chain &gt;/= 10 mg/dL AND abnormal
                  kappa/lambda ratio

          -  Evidence of underlying end organ damage and/or myeloma defining event attributed to
             underlying plasma cell proliferative disorder meeting at least one of the following:

               -  Hypercalcemia: serum calcium ?0.25 mmol/L (&gt; mg/dL) above upper limit of normal
                  or &gt;/= 2.75 mmoL (11 mg/dL)

               -  Anemia: hemoglobin value &lt;10 g/dL or &gt;2 g/dL below lower limit of normal

               -  Bone disease &gt;/= 1 lytic lesions on skeletal X-ray, CT, or PET-CT. For patients
                  with 1 lytic lesion, bone marrow should demonstrate &gt;/=10% clonal plasma cells

               -  Clonal bone marrow plasma cell percentage &gt;/=60%

               -  Involved/un-involved serum free light chain ratio &gt;/=100 and involved free light
                  chain &gt;/=100 mg/L

               -  &gt; 1 focal lesion on magnetic resonance imaging study (lesion must be &gt;5mm) in
                  size

               -  For patients with 1 lytic lesion, bone marrow should demonstrate â‰¥10% clonal
                  plasma cells

          -  Creatinine clearance &gt;/=60 ml/min. CrCl can be measured or estimated using
             Cockcroft-Gault method, MDRD, or CKD-EPI formulae

          -  Age &gt;/= 18 years at the time of signing the informed consent documentation. Age limit
             of &lt;/= 75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count (ANC) &gt;/= 1.0 K/uL, hemoglobin &gt;/= 8 g/dL, and platelet
             count &gt;/= 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of
             clinical investigator. Transfusions and growth factors are permissible.

          -  Adequate hepatic function, with bilirubin &lt; 1.5 x the ULN, and AST and ALT &lt; 3.0 x ULN

          -  All study participants must be able to tolerate one of the following
             thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin
             (Coumadin) or alternative anti-coagulant

          -  All study participants must be registered into the mandatory eREMS program and be
             willing and able to comply with the requirements of REMS

          -  Females of childbearing potential (FCBP)+ must have a negative serum or urine
             pregnancy test within 10-14 days and again within 24 hours prior to prescribing
             lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either
             commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
             methods of birth control, one highly effective method and one additional effective
             method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP
             must also agree to ongoing pregnancy testing. Men must agree to use a latex condom
             during sexual contact with a FCBP even if they have had a successful vasectomy.

               -  A female of childbearing potential is a sexually mature female who: 1) has not
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any
                  time in the preceding 24 consecutive months)

        Exclusion Criteria:

          -  Patients receiving &gt;1 cycle of prior treatment or concurrent systemic treatment for
             multiple myeloma:

               -  Treatment of hypercalcemia or spinal cord compression or aggressively progressing
                  myeloma with current or prior corticosteroids is permitted

               -  Bone targeting agents are permitted

               -  Concurrent or prior treatment with corticosteroids for indications other than
                  multiple myeloma is permitted

               -  Prior treatment with radiotherapy is permitted

               -  Prior treatment for smoldering myeloma is permitted with a washout period of 2
                  weeks from last dose. Smoldering patients previously treated carfilzomib are
                  excluded

               -  Patients with measurable disease who received up to one cycle of any therapy
                  within 60 days with a washout period of 2 weeks from last dose (on a trial or
                  outside a trial) are eligible (Note: Measurable disease is defined as one or more
                  of the following: Serum monoclonal protein â‰¥ 1.0 g/dL, Urine monoclonal protein â‰¥
                  200 mg/24 hour and/ or Involved serum immunoglobulin free light chain â‰¥ 10 mg/dL
                  AND abnormal kappa/lambda ratio)

          -  Plasma cell leukemia

          -  POEMS syndrome

          -  Amyloidosis

          -  Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1
             second (FEV1) &lt;50% of predicted normal (note that FEV1 testing is required for
             subjects suspected of having chronic obstructive pulmonary disease and subjects must
             be excluded ifFEV1 &lt;50% of predicted normal).

          -  Pregnant or lactating females. Because there is a potential risk for adverse events
             nursing infants secondary to treatment of the mother with carfilzomib in combination
             with lenalidomide. These potential risks may also apply to other agents used in this
             study.

          -  Uncontrolled hypertension (i.e. systolic BP &gt;160 mmHg, diastolic BP &gt; 100 mmHg) or or
             diabetes

          -  Active hepatitis B or C infection

          -  Subject is:

               -  Seropositive for human immunodeficiency virus (HIV)

               -  Seropositive for hepatitis B (defined by a positive test for hepatitis B surface
                  antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg
                  negative but positive for antibodies to hepatitis B core antigen [anti-HBc]
                  and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened
                  using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus
                  (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION:
                  Subjects with serologic findings suggestive of HBV vaccination (anti-HBs
                  positivity as the only serologic marker) AND a known history of prior HBV
                  vaccination, do not need to be tested for HBV DNA by PCR.

               -  Seropositive for hepatitis C (except in the setting of a sustained virologic
                  response[SVR], defined as aviremia at least 12 weeks after completion of
                  antiviral therapy).

          -  Has significant cardiovascular disease with NYHA Class III or IV symptoms, EF&lt;/=40% or
             hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction
             within 6months prior to enrollment, or unstable angina, or unstable arrhythmia as
             determined by history and physical examination. Echocardiogram will be performed
             during screening evaluation.

          -  &quot;Association Class III to IV), symptomatic ischemia, uncontrolled arrhythmias,
             screening ECG with corrected QT interval (QTc) of &gt; 470 msec, pericardial disease, or
             myocardial infarction within 4 months prior to randomization and Left ventricular
             ejection fraction &lt; 40% assessed by transthoracic echocardiogram (ECHO).&quot;

          -  Pulmonary hypertension

          -  Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease,
             or bowel resection that would prevent absorption of oral agents

          -  Uncontrolled intercurrent illness including but not limited to active infection or
             psychiatric illness/social situations that would compromise compliance with study
             requirements

          -  Significant neuropathy &gt;/= Grade 3 or Grade 2 neuropathy with pain at baseline

          -  Contraindication to any concomitant medication, including antivirals or
             anticoagulation.

          -  Major surgery within 3 weeks prior to first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ola Landgren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola Landgren, MD, PhD</last_name>
    <phone>646-608-2022</phone>
    <email>landgrec@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neha Korde, MD</last_name>
    <phone>212-639-7664</phone>
    <email>korden@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Hoffman, MD</last_name>
      <email>j.hoffman4@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken I. Shain, MD</last_name>
      <phone>888-663-3488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ange Paner, MD</last_name>
      <phone>888-352-7874</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital &amp; Clinics - Data Collection Only</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yogesh Jethava, MBBS</last_name>
      <phone>319-356-4200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (All Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Lendgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute - Data Collection Only</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Hillengass, MD</last_name>
      <phone>716-845-2300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Landgren, MD, PhD</last_name>
      <phone>646-608-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institue</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Sborov, MD</last_name>
      <phone>801-585-2626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SkÃ¥ne University Hospital</name>
      <address>
        <city>MalmÃ¶</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Hannson, MD</last_name>
      <phone>+46 40 33 10 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>VRD</keyword>
  <keyword>KRD</keyword>
  <keyword>KRD+DARA</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-339</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

